Zilia’s technology addresses an unmet clinical need: the early assessment of biomarkers related to eye disease, helping preserve vision. By combining imaging, spectrometry, and AI, it creates a new type of clinical data with potential applications in neurology, cardiology, oncology, and intensive care.
